KING OF PRUSSIA, Pa., March 9, 2026
CSL Limited, a global biopharmaceutical leader, has announced a $1.5 billion investment to expand its plasma-therapy manufacturing facility in Kankakee, Illinois, significantly strengthening the company’s U.S. production network for plasma-derived therapies (PDTs) used to treat rare and life-threatening diseases. The project, which builds on more than $3 billion already invested in CSL’s U.S. operations since 2018, is expected to create at least 300 new skilled jobs and around 800 construction roles, while enabling advanced manufacturing capabilities that support the growing global demand for critical biologic medicines. The expansion, which is scheduled to become operational by 2031, will further enhance the company’s ability to deliver life-saving treatments for conditions including hemophilia, primary immunodeficiency, and hereditary angioedema, while reinforcing the United States as a key hub in the company’s global biologics supply chain.
Expansion to Strengthen Plasma-Derived Therapy Production
The Illinois expansion represents a major milestone in CSL’s long-term strategy to increase manufacturing capacity for plasma-derived therapies, which rely on proteins extracted from donated human plasma to treat rare and complex diseases. The upgraded facility will integrate CSL’s Horizon 2 manufacturing process, a proprietary yield-enhancing technology designed to significantly increase immunoglobulin output from the same volume of plasma, improving efficiency while maintaining strict safety and quality standards required in biologics manufacturing.
According to company leadership, this advanced platform will help optimize production workflows and ensure more consistent supply of essential plasma-based medicines for patients around the world. Gordon Naylor, Chief Executive Officer and Managing Director of CSL, emphasized that the expansion reinforces the company’s commitment to addressing the rising global need for plasma therapies while strengthening one of the most important manufacturing hubs within its international network. The Kankakee facility already plays a vital role in the company’s production infrastructure and currently employs more than 1,200 full-time staff, making it one of the region’s key life-science manufacturing centers.
Advanced Manufacturing and Technology Integration
Advertisement
The expansion will introduce state-of-the-art biologics manufacturing technologies, enabling CSL to increase the efficiency and scalability of its plasma-protein production processes. The Horizon 2 platform is designed to maximize protein yield per gram of plasma, a critical improvement given the complexity of plasma-derived medicine manufacturing, which involves multiple highly regulated stages including plasma collection, testing, protein fractionation, viral clearance, purification, and formulation.
Unlike traditional pharmaceuticals that can be synthesized chemically, plasma therapies depend entirely on donated human plasma, making manufacturing capacity and process optimization essential for ensuring reliable supply. CSL’s leadership stated that the upgraded facility will support next-generation manufacturing methods that enhance productivity while maintaining the stringent cGMP quality and safety standards required in biologics production. The investment reflects the company’s broader effort to modernize its global manufacturing footprint and strengthen the resilience of supply chains for critical therapies.
Economic and Healthcare Impact
The project has also received strong support from government and regional leaders, who highlighted its importance for both patient access to life-saving medicines and economic development in Illinois. Illinois Governor JB Pritzker described the investment as a significant boost to the state’s life-science manufacturing sector and a vote of confidence in Illinois’ growing role as a hub for biotechnology innovation.
Local officials noted that the expansion will generate high-quality employment opportunities while strengthening domestic production capacity for essential medicines. Patient advocacy organizations also welcomed the development, emphasizing that reliable supply of plasma therapies remains critical for individuals living with rare disorders that require continuous treatment.
Manufacturing plasma-derived medicines is an especially complex and time-intensive process that can span several months, making long-term investments in infrastructure essential for maintaining global treatment availability. Since 2018, CSL has expanded its presence across the United States with more than 6,500 new jobs created nationwide, bringing its total U.S. workforce to nearly 19,000 employees, representing around 60% of the company’s global staff. The Kankakee expansion therefore represents both a major healthcare advancement and a strategic step toward strengthening biopharmaceutical manufacturing capacity for life-saving biologic therapies worldwide.
Source: CSL press release
